Dr. Reddy's Laboratories
Revenues dropped 20% year over year, largely because the most recent quarter was being compared to a whopper of a quarter. The year-ago quarter included revenues from authorized generics, as well as from exclusive marketing of its generic version of GlaxoSmithKline's
Dr. Reddy's bottom-line problems came because it's exposed to the turmoil in Germany's generic-drug market by way of its 2006 purchase of Betapharm. Price cuts and a shakeup in suppliers to the insurance companies forced Dr. Reddy's to take a $60 million charge in the quarter.
With further price cuts expected in April, the generic-drug maker is scrambling to make the best of the situation. It is moving manufacturing back to its home base in India, which will help with gross margins. By March, the company expects to have 60% of the products (by volume) being shipped to Germany. By summer, that should be up to 80%.
In the U.S., Dr. Reddy is making a push into the over-the-counter (OTC) generic-drug market. This month, it launched a generic version of Pfizer's
While the worst might be behind Dr. Reddy's, don't expect to see the company move back toward double-digit growth too soon. The fact that the company is touting its launch of a generic version of Glaxo's Imitrex four quarters from now makes me think that my pick for an attractive bargain stock is going to take awhile to turn around.
More Foolishness spicier than curry:
Pfizer is a pick of the Inside Value newsletter. If you'd like to know why, click here to grab a free 30-day trial and check out all past issues of the newsletter. If dividends are your thing, grab a subscription to the Income Investor newsletter; the team's picks include both Johnson & Johnson and Glaxo.